Analysts Set BioTelemetry Inc (BEAT) Target Price at $43.67

Shares of BioTelemetry Inc (NASDAQ:BEAT) have been given an average rating of “Hold” by the ten analysts that are presently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $43.67.

BEAT has been the topic of several recent analyst reports. BidaskClub raised BioTelemetry from a “strong sell” rating to a “sell” rating in a report on Tuesday, December 19th. Zacks Investment Research cut BioTelemetry from a “hold” rating to a “sell” rating in a report on Wednesday, January 31st. Dougherty & Co reaffirmed a “buy” rating and issued a $41.00 price target (up previously from $40.00) on shares of BioTelemetry in a report on Friday, February 23rd. Finally, TheStreet cut BioTelemetry from a “b-” rating to a “c” rating in a report on Tuesday, March 20th.

How to Become a New Pot Stock Millionaire

NASDAQ:BEAT opened at $30.60 on Wednesday. BioTelemetry has a twelve month low of $23.30 and a twelve month high of $39.20. The stock has a market capitalization of $1,032.51, a price-to-earnings ratio of 31.55, a price-to-earnings-growth ratio of 1.59 and a beta of 0.86. The company has a debt-to-equity ratio of 0.80, a quick ratio of 1.66 and a current ratio of 1.77.

BioTelemetry (NASDAQ:BEAT) last released its quarterly earnings results on Thursday, February 22nd. The medical research company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.08. BioTelemetry had a positive return on equity of 14.54% and a negative net margin of 5.56%. The firm had revenue of $91.70 million for the quarter, compared to analysts’ expectations of $88.33 million. During the same quarter last year, the firm posted $0.23 EPS. The company’s revenue was up 69.8% compared to the same quarter last year. research analysts expect that BioTelemetry will post 1.25 earnings per share for the current fiscal year.

In related news, insider Fred Broadway sold 54,158 shares of the firm’s stock in a transaction dated Tuesday, March 13th. The stock was sold at an average price of $34.17, for a total transaction of $1,850,578.86. Following the transaction, the insider now directly owns 64,880 shares of the company’s stock, valued at approximately $2,216,949.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 9.60% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Sterling Capital Management LLC purchased a new position in shares of BioTelemetry during the 4th quarter valued at about $12,910,000. MetLife Investment Advisors LLC purchased a new position in shares of BioTelemetry during the 4th quarter valued at about $397,000. Lyon Street Capital LLC raised its holdings in shares of BioTelemetry by 2,368.9% during the 4th quarter. Lyon Street Capital LLC now owns 379,029 shares of the medical research company’s stock valued at $11,333,000 after buying an additional 363,677 shares in the last quarter. Macquarie Group Ltd. raised its holdings in shares of BioTelemetry by 8,866.8% during the 4th quarter. Macquarie Group Ltd. now owns 756,263 shares of the medical research company’s stock valued at $22,612,000 after buying an additional 747,829 shares in the last quarter. Finally, Vident Investment Advisory LLC purchased a new position in shares of BioTelemetry during the 4th quarter valued at about $612,000. 87.64% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Analysts Set BioTelemetry Inc (BEAT) Target Price at $43.67” was first posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3338428/analysts-set-biotelemetry-inc-beat-target-price-at-43-67.html.

BioTelemetry Company Profile

BioTelemetry, Inc, a mobile and wireless medical technology company, provides cardiac and mobile blood glucose monitoring (BGM), centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries. It operates in three segments: Healthcare, Research, and Technology.

Analyst Recommendations for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

NamoCoin  Trading 16.2% Lower  Over Last Week
NamoCoin Trading 16.2% Lower Over Last Week
Brokerages Set LATAM Airlines Group  Target Price at $17.00
Brokerages Set LATAM Airlines Group Target Price at $17.00
Contrasting Walmart de M?xico y Centroam?rica  & Its Peers
Contrasting Walmart de M?xico y Centroam?rica & Its Peers
Brokerages Set Polar Capital  Target Price at $550.00
Brokerages Set Polar Capital Target Price at $550.00
Synchrony Financial  Expected to Post Quarterly Sales of $3.89 Billion
Synchrony Financial Expected to Post Quarterly Sales of $3.89 Billion
-$0.14 EPS Expected for CymaBay Therapeutics  This Quarter
-$0.14 EPS Expected for CymaBay Therapeutics This Quarter


Leave a Reply

© 2006-2018 Ticker Report. Google+.